Barclays PLC vs Canopy Growth Corp — how do they compare? Barclays PLC trades at $28.05 (market cap $92.56B), while Canopy Growth Corp trades at $0.97 (market cap $398.46M). The key difference: Barclays PLC is far larger — about 232.3× Canopy Growth Corp's market cap, and Barclays PLC pays a 1.67% dividend while Canopy Growth Corp pays none. Which is the better fit depends on your goals.
| BCS | CGC | |
|---|---|---|
Market Cap | $92.56B | $398.46M |
Sector | Financials | Health |
52-Week High | $28.41 | $1.92 |
52-Week Low | $18.48 | $0.86 |
Dividend Yield | 1.67% | — |
Enterprise Value | — | $337.90M |
Signals from Pluang's Aura AI — not financial advice
Barclays PLC (BCS) trades at $27.29, down 0.69% on the day, near its 52-week high of $28.43. The stock shows strong fundamental momentum with revenue rising to $29.14B in 2025 and net income reaching $7.17B, supported by three consecutive quarterly EPS beats. Technical indicators signal a bullish trend, while analyst sentiment remains positive with 68% buy ratings. Recent news highlights ongoing legal investigations but also underscores the bank's role in market analysis and product innovation.
The outlook for BCS is cautiously optimistic, driven by solid earnings growth and attractive valuation metrics like a P/E of 11.91 and P/B of 0.91. Key risks include potential legal liabilities from securities investigations and macroeconomic sensitivity. Investors should weigh the strong analyst support against these headwinds for balanced decision-making.
Canopy Growth (CGC) trades at $0.96, down 1.15% on the day, with a mixed technical picture showing a bullish overall signal but bearish moving averages. The company reported a net loss of $598.12 million in 2025, with revenue declining to $269 million, though recent quarterly earnings showed one beat and two misses against expectations. Cash flow remains negative, but the balance sheet shows improving debt-to-asset ratios, down to 33.13% in 2025 from 53.61% in 2023.
The outlook is cautious; while cost-cutting and restructuring efforts are underway, profitability remains elusive, and the stock faces risks including potential delisting due to low share price. Analyst sentiment is divided, with 33% recommending buy, 41% hold, and 26% sell. Investors should weigh the potential for a turnaround against significant operational and regulatory challenges in the cannabis sector.
Trailing returns across standard periods
Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments
Read more on BCS →Canopy Growth, headquartered in Smiths Falls, Canada, cultivates and sells medicinal and recreational cannabis, and hemp, through a portfolio of brands that include Tweed, Spectrum Therapeutics, and CraftGrow. Although it primarily operates in Canada, Canopy has distribution and production licenses in more than a dozen countries to drive expansion in global medical cannabis and also holds an option to acquire Acreage Holdings upon U.S. federal cannabis legalization.
Read more on CGC →